The raw feed
Latest filings
Every transaction from every Form 4, as filed, newest first. Open-market buys (P) and sells (S) become signals; the rest is shown for completeness.
| Date | Company | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|---|
| Aug 7, 2026 | CHYM Chime Financial, Inc. | Christopher R Britt Chief Executive Officer | CConversion Class A Common Stockindirect: See footnote10b5-1 | +83,000 | $0.00 | $0 | 83,000 | Aug 10, 2026 |
| Aug 7, 2026 | CHYM Chime Financial, Inc. | Christopher R Britt Chief Executive Officer | CConversion Class A Common Stockindirect: See footnote10b5-1 | +49,843 | $0.00 | $0 | 117,000 | Aug 10, 2026 |
| Aug 10, 2026 | CHYM Chime Financial, Inc. | Christopher R Britt Chief Executive Officer | CConversion Class A Common Stockindirect: See footnote10b5-1 | +150,000 | $0.00 | $0 | 150,000 | Aug 10, 2026 |
| Aug 6, 2026 | CHYM Chime Financial, Inc. | Christopher R Britt Chief Executive Officer | CConversion Class B Common Stockderivativeindirect: See footnote10b5-1 | -200,000 | $0.00 | $0 | 83,000 | Aug 10, 2026 |
| Aug 7, 2026 | CHYM Chime Financial, Inc. | Christopher R Britt Chief Executive Officer | CConversion Class B Common Stockderivativeindirect: See footnote10b5-1 | -83,000 | $0.00 | $0 | 0 | Aug 10, 2026 |
| Aug 7, 2026 | CHYM Chime Financial, Inc. | Christopher R Britt Chief Executive Officer | CConversion Class B Common Stockderivativeindirect: See footnote10b5-1 | -49,843 | $0.00 | $0 | 14,593,721 | Aug 10, 2026 |
| Aug 10, 2026 | CHYM Chime Financial, Inc. | Christopher R Britt Chief Executive Officer | CConversion Class B Common Stockderivativeindirect: See footnote10b5-1 | -150,000 | $0.00 | $0 | 14,443,721 | Aug 10, 2026 |
| Aug 6, 2026 | CHYM Chime Financial, Inc. | Ryan A King Co-Founder | CConversion Class A Common Stockindirect: See footnote10b5-1 | +337,898 | $0.00 | $0 | 375,000 | Aug 10, 2026 |
| Aug 6, 2026 | CHYM Chime Financial, Inc. | Ryan A King Co-Founder | CConversion Class B Common Stockderivativeindirect: See footnote10b5-1 | -337,898 | $0.00 | $0 | 11,845,841 | Aug 10, 2026 |
| Aug 10, 2026 | BLSM BlossomHill Therapeutics, Inc. | Sundeep Agrawal director | CConversion Common Stockindirect: By Brahma BlossomHill Partners, LLC | +578,524 | - | - | 578,524 | Aug 10, 2026 |
| Aug 10, 2026 | BLSM BlossomHill Therapeutics, Inc. | Sundeep Agrawal director | CConversion Series B Preferred Stockderivativeindirect: By Brahma BlossomHill Partners, LLC | -578,524 | - | - | 0 | Aug 10, 2026 |
| Aug 6, 2026 | PLTR Palantir Technologies Inc. | Shyam Sankar See Remarks | CConversion Class A Common Stock10b5-1 | +35,000 | - | - | 677,786 | Aug 10, 2026 |
| Aug 6, 2026 | PLTR Palantir Technologies Inc. | Shyam Sankar See Remarks | CConversion Class B Common Stockderivative10b5-1 | -35,000 | $0.00 | $0 | 3,628,598 | Aug 10, 2026 |
| Aug 10, 2026 | BLSM BlossomHill Therapeutics, Inc. | Jingrong Jean Cui President and CEO | CConversion Common Stockindirect: By The Li and Cui Family Trust | +1,600,682 | - | - | 1,600,682 | Aug 10, 2026 |
| Aug 10, 2026 | BLSM BlossomHill Therapeutics, Inc. | Jingrong Jean Cui President and CEO | CConversion Common Stockindirect: By The Li and Cui Family Trust | +113,435 | - | - | 1,714,117 | Aug 10, 2026 |
| Aug 10, 2026 | BLSM BlossomHill Therapeutics, Inc. | Jingrong Jean Cui President and CEO | CConversion Common Stockindirect: By RongShan, LLC | +124,779 | - | - | 124,779 | Aug 10, 2026 |
| Aug 10, 2026 | BLSM BlossomHill Therapeutics, Inc. | Jingrong Jean Cui President and CEO | CConversion Series Angel Preferred Stockderivativeindirect: By The Li and Cui Family Trust | -1,600,682 | - | - | 0 | Aug 10, 2026 |
| Aug 10, 2026 | BLSM BlossomHill Therapeutics, Inc. | Jingrong Jean Cui President and CEO | CConversion Series B Preferred Stockderivativeindirect: By The Li and Cui Family Trust | -113,435 | - | - | 0 | Aug 10, 2026 |
| Aug 10, 2026 | BLSM BlossomHill Therapeutics, Inc. | Jingrong Jean Cui President and CEO | CConversion Series B Preferred Stockderivativeindirect: By RongShan, LLC | -124,779 | - | - | 0 | Aug 10, 2026 |
| Aug 10, 2026 | BLSM BlossomHill Therapeutics, Inc. | Yishan Li Executive Chairman | CConversion Common Stockindirect: By The Li and Cui Family Trust | +1,600,682 | - | - | 1,600,682 | Aug 10, 2026 |
| Aug 10, 2026 | BLSM BlossomHill Therapeutics, Inc. | Yishan Li Executive Chairman | CConversion Common Stockindirect: By The Li and Cui Family Trust | +113,435 | - | - | 1,714,117 | Aug 10, 2026 |
| Aug 10, 2026 | BLSM BlossomHill Therapeutics, Inc. | Yishan Li Executive Chairman | CConversion Common Stockindirect: By RongShan, LLC | +124,779 | - | - | 124,779 | Aug 10, 2026 |
| Aug 10, 2026 | BLSM BlossomHill Therapeutics, Inc. | Yishan Li Executive Chairman | CConversion Series Angel Preferred Stockderivativeindirect: By The Li and Cui Family Trust | -1,600,682 | - | - | 0 | Aug 10, 2026 |
| Aug 10, 2026 | BLSM BlossomHill Therapeutics, Inc. | Yishan Li Executive Chairman | CConversion Series B Preferred Stockderivativeindirect: By The Li and Cui Family Trust | -113,435 | - | - | 0 | Aug 10, 2026 |
| Aug 10, 2026 | BLSM BlossomHill Therapeutics, Inc. | Yishan Li Executive Chairman | CConversion Series B Preferred Stockderivativeindirect: By RongShan, LLC | -124,779 | - | - | 0 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | James B. Tananbaum director, owner | CConversion Common Stockindirect: See footnote | +3,117,664 | - | - | 3,117,664 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | James B. Tananbaum director, owner | CConversion Common Stockindirect: See footnote | +445,320 | - | - | 3,562,984 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | James B. Tananbaum director, owner | CConversion Common Stockindirect: See footnote | +1,125,823 | - | - | 1,125,823 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | James B. Tananbaum director, owner | CConversion Common Stockindirect: See footnote | +742,201 | - | - | 1,868,024 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | James B. Tananbaum director, owner | CConversion Common Stockindirect: See footnote | +195,776 | - | - | 2,203,800 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | James B. Tananbaum director, owner | CConversion Common Stockindirect: See footnote | +3,117,664 | - | - | 3,117,664 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | James B. Tananbaum director, owner | CConversion Common Stockindirect: See footnote | +296,880 | - | - | 3,414,544 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | James B. Tananbaum director, owner | CConversion Series A-2 Convertible Stockderivativeindirect: See footnote | -3,117,664 | - | - | 0 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | James B. Tananbaum director, owner | CConversion Series B Convertible Preferred Stockderivativeindirect: See footnote | -445,320 | - | - | 0 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | James B. Tananbaum director, owner | CConversion Series A-2 Convertible Preferred Stockderivativeindirect: See footnote | -1,125,823 | - | - | 0 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | James B. Tananbaum director, owner | CConversion Series B Convertible Preferred Stockderivativeindirect: See footnote | -742,201 | - | - | 0 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | James B. Tananbaum director, owner | CConversion Series A-2 Convertible Preferred Stockderivativeindirect: See footnote | -3,117,664 | - | - | 0 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | James B. Tananbaum director, owner | CConversion Series B Convertible Preferred Stockderivativeindirect: See footnote | -296,880 | - | - | 0 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | James B. Tananbaum director, owner | CConversion Convertible Promissory Notederivativeindirect: See footnote | -195,776 | - | - | 0 | Aug 10, 2026 |
| Aug 6, 2026 | DDOG Datadog, Inc. | Amit Agarwal Chief Product Officer | CConversion Class A Common Stockindirect: By Trust10b5-1 | +20,000 | $0.00 | $0 | 21,640 | Aug 10, 2026 |
| Aug 6, 2026 | DDOG Datadog, Inc. | Amit Agarwal Chief Product Officer | CConversion Class B Common Stockderivativeindirect: By Trust10b5-1 | -20,000 | $0.00 | $0 | 210,059 | Aug 10, 2026 |
| Aug 10, 2026 | BLSM BlossomHill Therapeutics, Inc. | Bihua Chen director, owner | CConversion Common Stockindirect: See footnotes | +1,599,993 | - | - | 1,599,993 | Aug 10, 2026 |
| Aug 10, 2026 | BLSM BlossomHill Therapeutics, Inc. | Bihua Chen director, owner | CConversion Common Stockindirect: See footnotes | +1,701,541 | - | - | 3,301,534 | Aug 10, 2026 |
| Aug 10, 2026 | BLSM BlossomHill Therapeutics, Inc. | Bihua Chen director, owner | CConversion Series A Preferred Stockderivativeindirect: See footnotes | -1,599,993 | - | - | 0 | Aug 10, 2026 |
| Aug 10, 2026 | BLSM BlossomHill Therapeutics, Inc. | Bihua Chen director, owner | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -1,701,541 | - | - | 0 | Aug 10, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | Deep Track Biotechnology Master Fund, Ltd. owner | CConversion Common Stock | +1,957,138 | - | - | 1,957,138 | Aug 10, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | Deep Track Biotechnology Master Fund, Ltd. owner | CConversion Series C Redeemable Convertible Preferred Stockderivative | -18,181,818 | $0.00 | $0 | - | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Beth C Seidenberg director, owner | CConversion Common Stockindirect: See footnote | +938,979 | - | - | 1,368,532 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Beth C Seidenberg director, owner | CConversion Common Stockindirect: See footnote | +3,547,842 | - | - | 4,916,374 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Beth C Seidenberg director, owner | CConversion Common Stockindirect: See footnote | +1,027,635 | - | - | 5,944,009 | Aug 10, 2026 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.